SCHEMBL2460119

SCHEMBL2460119

CCC1(O)CC(c2nc(-c3cccc(OCc4ccccc4)c3)c3c(N)nccn23)C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 20/20 0.74
TNK2 Q07912 1/20 0.71
ROCK2 O75116 1/20 0.66
PRKD3 O94806 1/20 0.66
INSR P06213 1/20 0.66
LYN P07948 1/20 0.66
RET P07949 1/20 0.66
FGFR1 P11362 1/20 0.66
RPS6KB1 P23443 1/20 0.66
FLT4 P35916 1/20 0.66
FLT3 P36888 1/20 0.66
FRK P42685 1/20 0.66
STK3 Q13188 1/20 0.66
ROCK1 Q13464 1/20 0.66
PTK6 Q13882 1/20 0.66
ERBB4 Q15303 1/20 0.66
NTRK3 Q16288 1/20 0.66
AURKB Q96GD4 1/20 0.66
PRKD2 Q9BZL6 1/20 0.66
MKNK2 Q9HBH9 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457282 0.92 IGF1R (0.75) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2459673 0.92 IGF1R (0.76) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2459446 0.90 IGF1R (0.61) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2461617 0.90 IGF1R (0.71) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460210 0.89 IGF1R (0.73) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460637 0.89 IGF1R (0.73) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460213 0.89 IGF1R (0.73) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL3298039 0.86 TNK2 (0.59) IGF1RTNK2INSR
SCHEMBL2460633 0.85 IGF1R (0.82) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460634 0.85 IGF1R (0.82) IGF1RTNK2ROCK2PRKD3INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
CN-1898240-B Imidazopyrazine tyrosine kinase inhibitors OSI PHARM INC 2011-08-03 CN claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
EP-1675860-A2 IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-07-05 EP disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed
WO-2005037836-A2 IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885ROCK2 1384/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885ROCK2 1384/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885ROCK2 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.